Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching study of PF-06410293 and Humira in rheumatoid arthritis
2019-000284-24Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab, adalimumab-afzb and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum observed concentration and Area under the concentration-time curve over the dosing interval. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-000284-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000284-24.